Stockscreener 앱 받기
12.73
0.39%
-0.05
시간 외 거래:
12.72
-0.010
-0.08%
전일 마감가:
$12.78
열려 있는:
$12.96
하루 거래량:
91,837
Relative Volume:
0.44
시가총액:
$370.17M
수익:
$69.21M
순이익/손실:
$-61.98M
주가수익비율:
-4.9062
EPS:
-2.5947
순현금흐름:
$-9.61M
1주 성능:
-3.27%
1개월 성능:
-9.07%
6개월 성능:
-1.93%
1년 성능:
+72.03%
1일 변동 폭
$12.66
$13.16
1주일 범위
$12.41
$13.81
52주 변동 폭
$6.45
$17.15
Enanta Pharmaceuticals Inc Stock (ENTA) Company Profile
명칭
Enanta Pharmaceuticals Inc
전화
617 607 0800
주소
4 KINGSBURY AVENUE, WATERTOWN, MA
Compare ENTA vs VRTX, REGN, ARGX, RVMD, ALNY
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ENTA
Enanta Pharmaceuticals Inc
|
12.73 | 371.62M | 69.21M | -61.98M | -9.61M | -2.5947 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Enanta Pharmaceuticals Inc Stock (ENTA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-26 | 개시 | Rodman & Renshaw | Buy |
| 2025-11-14 | 개시 | JP Morgan | Overweight |
| 2025-10-01 | 업그레이드 | Jefferies | Hold → Buy |
| 2025-07-28 | 재개 | H.C. Wainwright | Buy |
| 2023-08-09 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2023-08-08 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-12-09 | 개시 | H.C. Wainwright | Buy |
| 2022-07-06 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2022-06-01 | 업그레이드 | Evercore ISI | Underperform → In-line |
| 2021-10-07 | 개시 | Jefferies | Buy |
| 2021-09-09 | 개시 | SVB Leerink | Mkt Perform |
| 2021-01-29 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2020-11-24 | 개시 | Evercore ISI | Underperform |
| 2020-08-28 | 재개 | ROTH Capital | Buy |
| 2020-08-26 | 개시 | Piper Sandler | Overweight |
| 2020-07-27 | 업그레이드 | JMP Securities | Mkt Perform → Mkt Outperform |
| 2020-03-17 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2019-11-22 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2019-09-26 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2019-05-24 | 개시 | Wolfe Research | Outperform |
| 2019-04-23 | 업그레이드 | Berenberg | Hold → Buy |
| 2018-12-13 | 개시 | Berenberg | Hold |
| 2018-06-06 | 개시 | ROTH Capital | Buy |
| 2018-02-08 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2018-01-02 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2017-11-21 | 재확인 | RBC Capital Mkts | Outperform |
| 2017-09-15 | 개시 | RBC Capital Mkts | Outperform |
| 2017-07-11 | 업그레이드 | JMP Securities | Mkt Perform → Mkt Outperform |
| 2016-04-28 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2016-02-09 | 재확인 | Barclays | Underweight |
| 2015-10-23 | 다운그레이드 | Barclays | Equal Weight → Underweight |
| 2015-10-23 | 업그레이드 | JMP Securities | Mkt Perform → Mkt Outperform |
모두보기
Enanta Pharmaceuticals Inc 주식(ENTA)의 최신 뉴스
ENTA|Enanta Pharmaceuticals Inc|Price:12.780|Chg%:-0.170 - TradingKey
Enanta Pharmaceuticals Inc (ENTA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Enanta Pharmaceuticals Inc (ENTA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Enanta Pharmaceuticals, Inc. Revenue Breakdown – NASDAQ:ENTA - TradingView
Enanta Pharmaceuticals (ENTA) Q1 2024 Earnings ReportResults, Call & Slides - TipRanks
Enanta Pharmaceuticals Inc (ENTA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Enanta Pharmaceuticals (9EP) Q2 2024 Earnings ReportResults, Call & Slides - TipRanks
Enanta Was First to File. Pfizer Still Won. The Difference Was One Digit. - JD Supra
Enterprise value to EBIT forward of Enanta Pharmaceuticals, Inc. – NASDAQ:ENTA - TradingView
Enanta v. Pfizer is Not About a Typo: It is About Possession of the Invention - IPWatchdog.com
Enterprise value to EBIT forward of Enanta Pharmaceuticals, Inc. – BX:9EP - TradingView
Enterprise value to EBITDA forward of Enanta Pharmaceuticals, Inc. – NASDAQ:ENTA - TradingView
(ENTA) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Enterprise value to EBITDA forward of Enanta Pharmaceuticals, Inc. – SWB:9EP - TradingView
Enterprise value to EBITDA forward of Enanta Pharmaceuticals, Inc. – DUS:9EP - TradingView
Enterprise value to EBIT forward of Enanta Pharmaceuticals, Inc. – DUS:9EP - TradingView
Enterprise value to EBIT forward of Enanta Pharmaceuticals, Inc. – GETTEX:9EP - TradingView
Enanta Pharmaceuticals outlines its antiviral pipeline. Focus on long-term opportunities for ENTA st - ad-hoc-news.de
Enanta Pharmaceuticals (ENTA) Rebounds 2.3% as Shares Approach Key Resistance ZoneUnusual Call Volume - dars.gov.et
Liquidity Mapping Around (ENTA) Price Events - Stock Traders Daily
Enanta Pharmaceuticals Establishes Flexible At-The-Market Offering - TipRanks
Enanta Enters $75 Million At-the-Market Stock Offering Agreement - Moomoo
Federal Circuit Rules Written Description Standard Governs Patent Priority In Enanta Pharmaceuticals v. Pfizer (PFE) - londoninsider.co.uk
Price to sales forward of Enanta Pharmaceuticals, Inc. – NASDAQ:ENTA - TradingView
Enanta Pharmaceuticals, Inc.(NasdaqGS:ENTA) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com
Enanta Pharmaceuticals, Inc.(NasdaqGS: ENTA) added to Russell 2500 Growth Benchmark - marketscreener.com
Enanta Pharmaceuticals, Inc.(NasdaqGS: ENTA) added to Russell 2000 Growth Benchmark - marketscreener.com
Enanta Pharmaceuticals, Inc.(NasdaqGS:ENTA) added to Russell 3000E Growth Benchmark - marketscreener.com
Enanta Pharmaceuticals, Inc.(NasdaqGS:ENTA) added to Russell Microcap Growth Benchmark Index - marketscreener.com
Enanta Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Vance Terry - Moomoo
Enanta Pharmaceuticals | SCHEDULE 13G/A: Others - Moomoo
Enanta Pharmaceuticals, Inc.(NasdaqGS: ENTA) added to Russell 3000 Growth Benchmark - marketscreener.com
AbbVie, Enanta announce EU label expansion for hepatitis C therapy, Maviret - MSN
Enanta Pharmaceuticals (ENTA) moves 5.2% higher: Will this strength last? - MSN
Enanta Pharmaceuticals sets out pipeline catalysts, shares watched by biotech investors - AD HOC NEWS
Enanta Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:ENTA) - TradingView
Pfizer patent win against Enanta over COVID pill upheld by appeals court - MSN
Price to book forward of Enanta Pharmaceuticals, Inc. – NASDAQ:ENTA - TradingView
Price to earnings forward of Enanta Pharmaceuticals, Inc. – NASDAQ:ENTA - TradingView
Enterprise value to revenue forward of Enanta Pharmaceuticals, Inc. – TRADEGATE:9EP - TradingView
Enterprise value to EBITDA forward of Enanta Pharmaceuticals, Inc. – TRADEGATE:9EP - TradingView
Price to book forward of Enanta Pharmaceuticals, Inc. – TRADEGATE:9EP - TradingView
ENTA Forecast — Price Target — Prediction for 2027 - TradingView
PATENT—Fed. Cir.: Pfizer Inc. prevails in coronavirus-treatment patent dispute with biotechnology company - VitalLaw.com
Enanta Pharmaceuticals (ENTA) Moves 5.2% Higher: Will This Strength Last? - Yahoo Finance
EC approves label expansion for Enanta’s Maviret in acute HCV infection - The Pharma Letter
Form 8K Enanta Pharmaceuticals Inc For: 23 June - Investing.com UK
Federal appeals court upholds invalidity of Enanta patent in Pfizer case By Investing.com - Investing.com South Africa
Form 8K Enanta Pharmaceuticals Inc For: 23 June By Investing.com - Investing.com South Africa
Federal appeals court upholds invalidity of Enanta patent in Pfizer case - Investing.com UK
H.C. Wainwright reiterates Enanta stock rating on FDA alignment - Investing.com UK
Enanta Pharmaceuticals Inc (ENTA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.97%
0.83%
자본화:
|
볼륨(24시간):